Completed PHASE4 INTERVENTIONAL 3-arm NCT03278132

Phase IV Clinical Trial, Immunogenicity and Safety of EV71 Vaccine

A Phase IV Open-labelled, Single-centered, Stratified-randomized Clinical Trial in Zhejiang Province to Evaluate the Safety and Immunogenicity of EV71 Vaccine Developed by Sinovac Biotech Co., Ltd.

Sponsor: Shangyu District Center for Disease Control and Prevention

Conditions Hand, Foot and Mouth Disease

Interventions EV71 vaccine

Updated 6 times since 2017 Last updated: Dec 28, 2018 Started: Jul 16, 2017 Primary completion: Sep 15, 2017 Completion: Sep 15, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03278132, this PHASE4 trial focuses on Hand, Foot and Mouth Disease and remains completed. Sponsored by Shangyu District Center for Disease Control and Prevention, it has been updated 6 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Feb 2019 — Jan 2021 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Jun 2018 — Feb 2019 [monthly]

Recruiting PHASE4

▶ Show 1 earlier version

Oct 2017 — Jun 2018 [monthly]

Recruiting PHASE4

First recorded

Jul 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shangyu District Center for Disease Control and Prevention
Sinovac Biotech Co., Ltd
Zhejiang Provincial Center for Disease Control and Prevention

Data source: Sinovac Biotech Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shaoxing, China